Veredus Laboratories Launches Powerful Multiplexed Molecular

Veredus Laboratories Launches Powerful Multiplexed Molecular
Diagnostic Lab-on-Chip Targeting Global Threat of
Multi-Drug-Resistant Tuberculosis 
SINGAPORE -- (Marketwire) -- 11/07/12 --   Veredus Laboratories, a
leading supplier of innovative molecular diagnostic tools, has
launched VereMTB(TM), a multiplexed molecular diagnostic chip capable
of fast and accurate detection of Mycobacterium Tuberculosis Complex
(MTBC) and its mutations, as well as 9 other clinically relevant
non-tubercular mycobacterium. These mutations are responsible for
resistance to multiple drugs and are reinvigorating the global spread
of Tuberculosis.  
The rise of multi-drug-resistant Tuberculosis (TB) is a global
healthcare challenge. Effective treatment of TB involves accurate and
fast diagnosis followed by a strict regimen of the right drugs.
Shortcomings in this treatment can cause the TB infection to mutate
into drug-resistant strains that can become increasingly difficult
and expensive to treat. Conventional methods of accurately
identifying TB infections can take up to 8 weeks. In contrast,
VereMTB can complete the diagnosis and identify the specific
mycobacterium causing the infection and drug resistance in less than
3 hours from natural samples*, avoiding the need for culturing, the
most time-consuming part of the traditional method. Additionally due
to its compact size, the system can be deployed in a wide range of
settings at point-of-need. 
"In 2011, 8.7 million people were diagnosed with TB and 1.4 million
people died from the disease. With its ranking by the World Health
Organization as the second greatest killer from a single infectious
agent worldwide[1], faster diagnosis and appropriate treatment of
this highly infectious disease is critical," said Dr. Rosemary Tan,
Chief Executive Officer of Veredus Laboratories. "We believe VereMTB
fulfills a crucial need in the timely diagnosis of TB and its
multi-drug resistance thus ensuring proper treatment." 
The VereMTB multiplexed molecular diagnostic Lab-on-Chip was designed
and tested through the TM-REST** program, as part of the European 7th
Framework to develop new diagnostics to fight TB and malaria.  
"STMicroelectronics is at the forefront of creating silicon
technology targeted at healthcare applications," s
aid Benedetto
Vigna, Executive VP & General Manager, Analog, MEMS & Sensors Group,
STMicroelectronics. "Our sensor and power-related technologies have
enabled numerous innovations in healthcare, ranging from personal and
portable to miniaturized and minimally-invasive devices. Using ST's
Lab-on-Chip technology, VereMTB is a clear demonstration of ST's
ability to leverage its technology portfolio as a strategic solution
to address a global healthcare burden." 
Based on STMicroelectronics' industry-proven Lab-on-Chip technology,
the VereMTB chip is currently undergoing evaluations by the Chinese
Center for Disease Control and Prevention in Beijing, China as part
of their ongoing program to assess new technologies for TB
diagnostics. According to the 2012 World Health Organization report
on TB, India and China combined have almost 40 percent of the world's
TB cases, and nearly 60% of multi-drug resistant cases in 2011 were
in India, China, and the Russian Federation. 
"At the main CDC National TB Reference Lab in Beijing, we have been
evaluating VereMTB using samples, collected from across China with a
special interest in detecting challenging multi-drug resistant
strains that are difficult to detect using other methods," said
Professor Zhao Yanlin Director of National TB Reference Laboratory
and Vice Director of the National Center for Tuberculosis Control and
Prevention at the Chinese Center for Disease Control and Prevention.
"The speed, accuracy and comprehensiveness of the results have been
very promising. We look forward to continuing our collaboration with
Veredus for new breakthroughs in diagnosing TB." 
VereMTB will be on display at the 43rd Union World Conference on Lung
Health in Kuala Lumpur, Malaysia on 13 - 17 Nov 2012 - Booth 67,
Kuala Lumpur Convention Centre. Veredus Laboratories is the
Singapore-based subsidiary of STMicroelectronics (NYSE: STM), a
global semiconductor leader in sensor technologies, including
biosensors such as the Lab-on-Chip. 
Notes to Editors:  
* Natural samples refer to direct sputum coughed out by TB patients. 
** The European funded consortium included STMicroelectronics,
University of Sienna (Italy), University of Glasgow (United Kingdom),
University of London (United Kingdom), Samara Oblast TB Service
(Russian Federation), National Reference Center for Mycobacterium
(Germany), University Hospital of Lung Diseases (Albania), National
Centre for Infectious and Parasitic Diseases (Bulgaria), and
Foundation for Innovative New Diagnostics (Switzerland). The lead
clinical development member was the San Raffaele Scientific Institute
of Milan, Italy. As part of the program VereMTB was tested on samples
from Samara (Russian Federation), Sofia (Bulgaria), and Tirana
(Albania). VereMTB has also recently undergone trials in Kampala,
About Veredus Laboratories Pte Ltd
 Veredus Laboratories Pte Ltd was
founded in 2003 and launched its first products in 2005. Veredus is a
Singapore-based majority-owned subsidiary of STMicroelectronics
(NYSE: STM), a global semiconductor leader serving customers across
the spectrum of electronics applications.  
Veredus specializes in the development, manufacture, and marketing of
innovative multiplexed molecular solutions in the clinical,
specialty, and custom testing markets based on STMicroelectronics'
proprietary Lab-on-Chip platform. The Lab-on-Chip platform, marketed
as the VerePLEX(TM) biosystem, combines
Micro-Electro-Mechanical-Systems (MEMS) with micro-fluidics to
integrate multiplexed DNA amplification with microarray detection for
rapid, cost-effective, and accurate analysis of biological materials. 
About STMicroelectronics
 ST is a global leader in the semiconductor
market serving customers across the spectrum of sense and power
technologies and multimedia convergence applications. From energy
management and savings to trust and data security, from healthcare
and wellness to smart consumer devices, in the home, car and office,
at work and at play, ST is found everywhere microelectronics make a
positive and innovative contribution to people's life. By getting
more from technology to get more from life, ST stands for
In 2011, the Company's net revenues were $9.73 billion. Further
information on ST can be found at 
VereMTB PR : 
For further information, please contact: 
Hazelle Lam
Director, Sales and Marketing
Veredus Laboratories Pte Ltd
Mobile: +65 9431 3790
Boey Taik Boon
Corporate External Communications
STMicroelectronics Asia-Pacific
Tel: +65 6427 7765
Press spacebar to pause and continue. Press esc to stop.